Abstract
Amyloidosis is a clinical disorder caused by deposition of proteins that abnormally self-assemble into insoluble fibrils and impair organ function. More than 20 unrelated precursor proteins lose their native structure and misfold, leading to the formation of amyloid fibrils. The latter share cross-β core structure in vivo and in vitro and gain abnormal functions. Local amyloid deposition occurs in the central nervous system in Alzheimers disease (AD) and cerebral amyloid angiopathy. AD is the most common form of neurodegenerative disorder, with dementia in the elderly as well as dementia with Lewy bodies (DLB). Extracellular deposition of amyloid β-peptide (Aβ) has been implicated as a critical step in the pathogenesis of AD. Involvement of neuroinflammation and microglial activation has been emphasized in the AD brain. Recent epidemiological studies have shown that long-term therapeutic use of non-steroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD and delayed the onset of AD. We review epidemiological studies of anti-AD effects of NSAIDs, experimental studies of anti-amyloidogenic as well as anti-inflammatory effects of NSAIDs, and recent clinical trials for AD with NSAIDs. We refer to the anti-fibrillogenic and fibril-destabilizing activities of NSAIDs for other proteins that can aggregate and form amyloid-like fibrils, including α-synuclein in DLB. The anti-amyloidogenic properties of some NSAIDs provide new insights for future therapeutic and preventative opportunities for AD and other amyloidoses, and protein-misfolding disorders.
Keywords: Alzheimer's disease, amyloid β-peptide (Aβ), amyloidosis, α-synuclein fibrils, central nervous system, neuroinflammation, non-steroidal anti-inflammatory drugs (NSAIDs), protein-misfolding disorders
Current Pharmaceutical Design
Title: Non-Steroidal Anti-Inflammatory Drugs as Anti-Amyloidogenic Compounds
Volume: 14 Issue: 30
Author(s): Mie Hirohata, Kenjiro Ono and Masahito Yamada
Affiliation:
Keywords: Alzheimer's disease, amyloid β-peptide (Aβ), amyloidosis, α-synuclein fibrils, central nervous system, neuroinflammation, non-steroidal anti-inflammatory drugs (NSAIDs), protein-misfolding disorders
Abstract: Amyloidosis is a clinical disorder caused by deposition of proteins that abnormally self-assemble into insoluble fibrils and impair organ function. More than 20 unrelated precursor proteins lose their native structure and misfold, leading to the formation of amyloid fibrils. The latter share cross-β core structure in vivo and in vitro and gain abnormal functions. Local amyloid deposition occurs in the central nervous system in Alzheimers disease (AD) and cerebral amyloid angiopathy. AD is the most common form of neurodegenerative disorder, with dementia in the elderly as well as dementia with Lewy bodies (DLB). Extracellular deposition of amyloid β-peptide (Aβ) has been implicated as a critical step in the pathogenesis of AD. Involvement of neuroinflammation and microglial activation has been emphasized in the AD brain. Recent epidemiological studies have shown that long-term therapeutic use of non-steroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD and delayed the onset of AD. We review epidemiological studies of anti-AD effects of NSAIDs, experimental studies of anti-amyloidogenic as well as anti-inflammatory effects of NSAIDs, and recent clinical trials for AD with NSAIDs. We refer to the anti-fibrillogenic and fibril-destabilizing activities of NSAIDs for other proteins that can aggregate and form amyloid-like fibrils, including α-synuclein in DLB. The anti-amyloidogenic properties of some NSAIDs provide new insights for future therapeutic and preventative opportunities for AD and other amyloidoses, and protein-misfolding disorders.
Export Options
About this article
Cite this article as:
Hirohata Mie, Ono Kenjiro and Yamada Masahito, Non-Steroidal Anti-Inflammatory Drugs as Anti-Amyloidogenic Compounds, Current Pharmaceutical Design 2008; 14 (30) . https://dx.doi.org/10.2174/138161208786404173
DOI https://dx.doi.org/10.2174/138161208786404173 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Socio-economic Aspects of Alzheimer's Disease
Current Alzheimer Research Recent Developments in PET Instrumentation
Current Pharmaceutical Biotechnology Acetylcholinesterase: Molecular Modeling with the Whole Toolkit
Current Topics in Medicinal Chemistry Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder
Current Pharmaceutical Design Subject index to volume 1
Current HIV Research Derivatives of Resveratrol: Potential Agents in Prevention and Treatment of Cardiovascular Disease
Current Medicinal Chemistry The Impact of Docosahexaenoic Acid on Alzheimer’s Disease: Is There a Role of the Blood-Brain Barrier?
Current Clinical Pharmacology Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
Current Drug Safety Connected Speech Deficit as an Early Hallmark of CSF-defined Alzheimer’s Disease and Correlation with Cerebral Hypoperfusion Pattern
Current Alzheimer Research Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets Quantitative and Mechanistic Studies of Aβ Immunotherapy
CNS & Neurological Disorders - Drug Targets Current Progresses of Novel Natural Products and Their Derivatives/ Analogs as Anti-Alzheimer Candidates: an Update
Mini-Reviews in Medicinal Chemistry Models of Infection Before and After Stroke: Investigating New Targets
Infectious Disorders - Drug Targets Growth and Trophic Factors, pH and the Na+/H+ Exchanger in Alzheimers Disease, Other Neurodegenerative Diseases and Cancer: New Therapeutic Possibilities and Potential Dangers
Current Alzheimer Research Methylphenidate on Cognitive Improvement in Patients with Traumatic Brain Injury: A Meta-Analysis
Current Neuropharmacology Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Current Bioinformatics A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Prospects of Magnetic Resonance Spectroscopy in Mouse Models of Alzheimers Disease
Current Medical Imaging